[Skip to Navigation]
October 1990

Systemic Amiloride Inhibits Experimentally Induced Neovascularization

Author Affiliations

From the The Wilmer Ophthalmological Institute, The Johns Hopkins Hospital, Baltimore, Md.

Arch Ophthalmol. 1990;108(10):1474-1476. doi:10.1001/archopht.1990.01070120122041

• Amiloride is an inhibitor of urokinase-type plasminogen activator, and might therefore have an inhibitory effect on neovascularization. Neovascularization was induced in rabbit corneas via local implantation of prostaglandin E, pellets prepared in a slow-release polymer. Animals received daily intraperitoneal injections of 30 mg of amiloride, or an equivalent volume of saline solution for 5 days; both were well tolerated without severe untoward effect. Neovascular response, as documented by corneal photographs, was evaluated after 5 days of injections. The area of induced corneal neovascularization was decreased by 55% in animals receiving amiloride when compared with controls. Thus, amiloride and similar compounds may prove useful in the study and management of neovascularization.

Add or change institution